Bliss GVS Pharma Ltd. displays moderate growth and valuation metrics relative to its peers, with certain strengths in profitability and low debt levels, making it a stable choice in the pharmaceuticals sector. However, it lags behind the top performers in terms of growth and efficiency, suggesting that it may not capitalize on the same growth trajectory as others like Mankind Pharma and Dr. Reddy's Laboratories.

• • Bliss GVS Pharma has a low debt-equity ratio of 0.0915, indicating strong financial health.
• • Its revenue growth (YoY) is lower than peers, but profitability margins are respectable.
• • The company presents a moderate valuation with a PE of 24.20, suggesting it is neither undervalued nor overvalued compared to its peers.